Home Endocrinology & Hormones Estrogen/progestogen Receptor antagonist Brilanestrant (GDC-0810) For research use only.

Brilanestrant (GDC-0810)

Synonyms: ARN-810

Brilanestrant (GDC-0810, ARN-810） is a potent ER-α binder (ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear hormone receptors.

Brilanestrant (GDC-0810) Chemical Structure

Brilanestrant (GDC-0810) Chemical Structure

CAS No. 1365888-06-7

Purity & Quality Control

Batch: S785501 DMSO]89 mg/mL]false]Ethanol]89 mg/mL]false]Water]Insoluble]false Purity: 99.98%
99.98

Brilanestrant (GDC-0810) Related Products

Signaling Pathway

Estrogen/progestogen Receptor Signaling Pathways

Estrogen/progestogen Receptor Signaling Pathway

Biological Activity

Description Brilanestrant (GDC-0810, ARN-810） is a potent ER-α binder (ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear hormone receptors.
Targets
ERα [1]
(Cell-free)		 ERβ [1]
(Cell-free)
6.1 nM 8.8 nM
In vitro
In vitro In cell-free radio-ligand competitive binding assays, GDC-0810 binds both ERα and ERβ with low nanomolar affinity[2]. GDC-0810 has little to no inhibition against CYP1A2, CYP2D6, or CYP3A4 (IC50 > 20 μM), modest inhibitory effect on CYP2C9 and CYP2C19 (IC50 = 2.2 and 3.3 μM respectively), and potent inhibition of CYP2C8 (IC50 of <0.1 μM). Selectivity of GDC-0810 over other nuclear hormone receptors is also found to be good. In transcriptional reporter assays for the mineralocorticoid (MR), progesterone-A (PR-A), progesterone (PR-B), and glucocorticoid (GR) receptors, GDC-0810 has minimal activity (IC50 > 1 μM). While in binding assays, GDC-0810 displays little activity toward the androgen receptor (AR; IC50 > 4 μM) and GR (IC50 = 0.99 μM)[1]. GDC-0810-mediated ERα depletion is dependent on the 26S proteasome. GDC-0810 antagonizes ERα ligand binding domain mutants in vitro and in vivo. In cell-free E2 competitive binding assays that was used to determine the binding of GDC-0810 to ER.WT, ER.Y537S and ER.D538G ligand binding domains, GDC-0810 retains its ability to potently displace E2 from the ligand binding domain, albeit with a slightly increased IC50 (WT: 2.6 nM vs. ER.Y537S: 5.5 nM and ER.D538G: 5.4 nM). GDC-0810 can compete the PGC1α co-activator peptide off the mutated ligand binding domain, implying that GDC-0810 is capable of driving an 'active' to 'inactive' conformational shift of mutant ER, though with a ~five-seven fold reduction in biochemical potency compared to wild-type ER[2].
Cell Research Cell lines MCF-7 cells
Concentrations --
Incubation Time 4 h
Method

MCF-7 cells are trypsinized and washed twice in phenol red free RPMI containing 5% charcoal dextran stripped FBS with 20 mM HEPES and NEAA and adjusted to a concentration of 200000 cells per mL with the same medium. Next, 16 μL of the cell suspension (3200 cells) is added to each well of a poly-D-lysine coated 384-well plate, and the cells are incubated at 37℃ over 4 days to allow the cells to adhere and grow. On day 4, a 10-point, serial 1:5 dilution of each compound is added to the cells in 16 μL at a final concentration ranging from 10−5 M to 5.12 × 10−12 M or 10−6 M to 5.12 × 10−13 M for fulvestrant. At 4 h post compound addition, the cells are fixed by adding 16 μL of 30% formalin to the 32 μL of cells and compound (10% formalin final concentration) for 20 min. Cells are then washed twice with PBS Tween 0.1% and then permeabilized in PBS 0.1% Triton (50 μL/well) for additional 15 min. The PBS 0.1% triton is decanted, and the cells are washed: LI-COR blocking buffer (50 μL/well) was added, the plate is spun at 3000 rpm, and then the blocking buffer is decanted. Additional LI-COR blocking buffer (50 μL/well) is added, and the cells are incubated overnight at 4℃. The blocking buffer is decanted, and the cells are incubated overnight at 4℃ with SP1 anti-ER rabbit monoclonal antibody diluted 1:1000 in LI-COR blocking buffer/0.1% Tween-20. Wells, which are treated with blocking buffer with Tween but no antibody, are used as a background control. Wells are washed twice with PBS Tween 0.1% to remove free SP1 antibodies, and the cells are incubated at room temp for 60−90 min in LI-COR goat antirabbit IRDyeTM 800CW (1:1000) and DRAQ5 DNA dye diluted in LI-COR blocking buffer containing 0.1% Tween-20 and 0.01% SDS. Cells are then washed with 0.1%Tween-20/PBS three times. Plates are scanned on a LI-COR Odyssey infrared imaging system.
In Vivo
In vivo The pharmacokinetic profile of GDC-0810 shows it is a low clearance molecule across species, with good bioavailability (40−60%). As would be expected for a lipophilic carboxylic acid, the compound is highly bound to plasma proteins (>99.5% across species) and has a low to moderate volume of distribution (Vss = 0.2−2.0 L/kg across species). GDC-0810 exhibits good bioavailability across species and displays robust activity in tamoxifen-sensitive and tamoxifen-resistant xenograft models of breast cancer[1]. GDC-0810 displays mild estrogenic activity in uterine models in vitro and in vivo[2].
Animal Research Animal Models a tamoxifen-sensitive MCF-7 xenograft model
Dosages 30 and 100 mg/kg
Administration p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802670 Completed
Healthy Volunteers
Genentech Inc.
 May 2016 Phase 1
NCT02621957 Completed
Breast Cancer
Genentech Inc.
 December 2015 Phase 1
NCT02569801 Terminated
Breast Cancer
Genentech Inc.
 December 4 2015 Phase 2
NCT01823835 Terminated
Breast Cancer
Genentech Inc.
 December 29 2014 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 446.90 Formula

C26H20ClFN2O2
CAS No. 1365888-06-7 SDF --
Smiles CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 89 mg/mL ( (199.14 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 89 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Brilanestrant (GDC-0810) | Brilanestrant (GDC-0810) supplier | purchase Brilanestrant (GDC-0810) | Brilanestrant (GDC-0810) cost | Brilanestrant (GDC-0810) manufacturer | order Brilanestrant (GDC-0810) | Brilanestrant (GDC-0810) distributor